price
CA
NASDAQ · CAI
Caris Life Sciences, Inc.
Healthcare · Biotechnology
$28.50
Up+$2.45 (+9.40%)
Updated Sep 16, 2026, 9:17 AM
SID Score
5.6/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 7.49B
- P/E ratio
- -34.61
- Dividend yield
- 0.00%
- 52-week range
- $14.19 – $29.32
- Volume
- 8.84M
- Avg. volume
- 1.42M
Price performance
CAI price history
1M range · 20 trading sessions · Daily adjusted prices
CAI closed at $28.50 after 20 trading sessions, up 35.91% for the selected period.
- Last close
- $28.50
- Period change
- +35.91%
- Period low
- $20.97
- Period high
- $28.50
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $25.80 | $28.675 | $25.80 | $28.50 | 8.84M |
| Sep 14, 2026 | $24.24 | $26.18 | $24.05 | $26.05 | 3.64M |
| Sep 11, 2026 | $24.16 | $24.67 | $24.09 | $24.34 | 1.82M |
| Sep 10, 2026 | $23.20 | $24.68 | $23.20 | $24.04 | 2.63M |
| Sep 9, 2026 | $24.00 | $24.96 | $23.95 | $24.03 | 3.15M |
| Sep 8, 2026 | $25.03 | $25.68 | $24.74 | $24.82 | 4.58M |
| Sep 4, 2026 | $24.88 | $25.14 | $24.4718 | $25.07 | 4.71M |
| Sep 3, 2026 | $24.94 | $25.34 | $23.62 | $25.32 | 6.43M |
| Sep 2, 2026 | $25.13 | $25.615 | $24.505 | $24.80 | 5.49M |
| Sep 1, 2026 | $25.60 | $25.62 | $24.55 | $24.78 | 4.03M |
| Aug 31, 2026 | $25.35 | $25.56 | $24.48 | $25.49 | 5.87M |
| Aug 28, 2026 | $26.15 | $26.75 | $25.47 | $25.63 | 3.84M |
| Aug 27, 2026 | $26.82 | $27.385 | $26.36 | $26.38 | 10.9M |
| Aug 26, 2026 | $27.70 | $28.0895 | $26.26 | $26.82 | 4.03M |
| Aug 25, 2026 | $26.19 | $28.32 | $25.77 | $28.01 | 6.82M |
| Aug 24, 2026 | $25.84 | $26.66 | $25.40 | $26.13 | 5.8M |
| Aug 21, 2026 | $24.73 | $26.60 | $24.32 | $26.27 | 6.39M |
| Aug 20, 2026 | $22.59 | $24.765 | $22.59 | $24.58 | 6.03M |
| Aug 19, 2026 | $21.92 | $22.94 | $21.92 | $22.76 | 6.56M |
| Aug 18, 2026 | $21.31 | $21.64 | $20.78 | $20.97 | 3.6M |
Latest CAI news
The latest Smart Investors Daily articles mentioning CAI.
Stock researchCompany · Overview
CAI research
Overview
Company profile and research snapshot.
Company profile
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $35.00
- Implied upside
- —
- Analysts
- 12
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | UBS | Neutral | — |
| Aug 6, 2026 | Evercore ISI Group | Outperform | — |
| Aug 6, 2026 | BTIG | Buy | — |
| Jul 6, 2026 | Evercore ISI Group | Outperform | — |
| Jul 2, 2026 | BTIG | Buy | — |
News briefing
Data unavailable
Market data is busy. Please try again shortly.
AI research layers
Interpretive context generated from the platform’s current data sources.
Data unavailable
Market data is busy. Please try again shortly.